Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ROCHE's PURCHASE OF SYNTEX WILL NOT AFFECT ALEVE

This article was originally published in The Tan Sheet

Executive Summary

ROCHE's PURCHASE OF SYNTEX WILL NOT AFFECT ALEVE, P&G said in response to the announcement that Hoffmann-La Roche has signed an agreement to acquire Syntex. A Procter & Gamble spokesperson said the company plans to begin shipping the new naproxen sodium-based OTC analgesic "over the next few weeks" under a development and marketing joint venture arrangement with Syntex. The P&G/Syntex joint venture also markets the analgesic Percogesic and has options to develop future Rx-to-OTC switches.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel